The estimated Net Worth of Biosciences Inc Neurocrine is at least $53.9 Milione dollars as of 23 February 2023. Biosciences Neurocrine owns over 4,395,588 units of Voyager Therapeutics Inc stock worth over $53,852,984 and over the last 6 years Biosciences sold VYGR stock worth over $0.
Sign up
Biosciences Neurocrine VYGR stock SEC Form 4 insiders trading
Biosciences has made over 2 trades of the Voyager Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Biosciences bought 4,395,588 units of VYGR stock worth $39,032,821 on 23 February 2023.
The largest trade Biosciences's ever made was buying 4,395,588 units of Voyager Therapeutics Inc stock on 23 February 2023 worth over $39,032,821. On average, Biosciences trades about 4,287,658 units every 722 days since 2019. As of 23 February 2023 Biosciences still owns at least 8,575,316 units of Voyager Therapeutics Inc stock.
You can see the complete history of Biosciences Neurocrine stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Biosciences Neurocrine's mailing address?
Biosciences's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Insiders trading at Voyager Therapeutics Inc
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 e Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
What does Voyager Therapeutics Inc do?
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
What does Voyager Therapeutics Inc's logo look like?
Complete history of Biosciences Neurocrine stock trades at Voyager Therapeutics Inc
Voyager Therapeutics Inc executives and stock owners
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Omar Khwaja,
Chief Medical Officer and Head of Research and Development -
Robert Hesslein,
Senior Vice President, General Counsel -
G. Andre Turenne,
President, Chief Executive Officer, Director -
G. Andre Turenne,
Advisor -
Dr. Omar Khwaja M.D., Ph.D.,
Chief Medical Officer and Head of R&D -
Robert W. Hesslein,
Sr. VP & Gen. Counsel -
james Geraghty,
Independent Director -
Steven Hyman,
Independent Director -
Michael J. Higgins M.B.A.,
Interim CEO, Pres & Chairman -
Dr. Glenn F. Pierce M.D., Ph.D.,
Independent Director, Interim Chief Scientific Officer & Chief Medical Officer -
Dr. Steven M. Paul M.D.,
Exec. Science Advisor & Director -
Nancy Vitale,
Director -
Michelle Smith,
Chief Human Resource Officer -
Kelly Bales,
Senior Vice President, Head of Neuroscience -
Allison Dorval,
Chief Financial Officer -
Robin Swartz,
Chief Operating Officer -
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.,
Pres, CEO & Director -
Julie Burek,
VP of Fin. -
Dr. Mark A. Kay M.D., Ph.D.,
Founder -
Dr. Phillip D. Zamore,
Founder -
Dr. Mark A. Kay,
Founder -
Dr. Guangping Gao,
Founder -
Dr. Krystof Bankiewicz M.D., Ph.D.,
Founder -
Toby Ferguson,
Chief Medical Officer -
Sandell Jacquelyn Fahey,
Chief Legal Officer -
Rock Ventures Iii, L.P.Thir...,
-
Jane Henderson,
Sr. V.P. & CFO, Corp. Dev. -
Wendy L Dixon,
Director -
Jeff Goater,
Chief Financial Officer -
Sanofi,
-
Perry A Karsen,
Director -
Harbor Master Investors (Ca...,
10% owner -
Bernard Ravina,
Chief Medical Officer -
Matthew P. Ottmer,
Chief Operating Officer -
Dinah Ph.D. Sah,
Chief Scientific Officer -
Steven M Paul,
Director -
Andre Turenne,
President & CEO -
Robin Swartz,
Chief Operating Officer -
Biosciences Inc Neurocrine,
10% owner -
Michael J Higgins,
Director -
Mark J Levin,
Director -
Glenn Pierce,
Director -
Julie Burek,
VP, Finance -
Todd Alfred Carter,
Chief Scientific Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Rock Ventures Iii, L.P.Thir...,
-
Catherine J Mackey,
Director -
Jude Onyia,
Director -
Grace Colon,
Director -
Capital, Llc Eco R1,
10% owner -
George A Scangos,
Director -
Nathan D. Jorgensen,
Chief Financial Officer